Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence …
Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease burden and burden prevented by vaccination for …
**Background**: Seasonal influenza causes an estimated 100,000–710,000 hospitalizations annually in the United States (U.S.). Treatment with antiviral medications, such as oseltamivir, can reduce risks of hospitalization among people with …
Isolation of symptomatic infectious persons can reduce influenza transmission. However, virus shedding that occurs without symptoms will be unaffected by such measures. Identifying effective isolation strategies for influenza requires understanding …
The generation time, representing the interval between infections in primary and secondary cases, is essential for understanding and predicting the transmission dynamics of seasonal influenza, including the real-time effective reproduction number …
**Background** Novel influenza viruses pose a potential pandemic risk. Rapid detection of novel influenza virus infection in humans is critical to characterizing the virus and facilitating the implementation of public health response measures. …
Before the COVID-19 pandemic, the role of asymptomatic influenza virus infections in influenza transmission was uncertain. However, the importance of asymptomatic infection with SARS-CoV-2 for onward transmission of COVID-19 has led experts to …
**Background** Antiviral chemoprophylaxis is recommended for use during influenza outbreaks in nursing homes to prevent transmission and severe disease among non-ill residents. Centers for Disease Control and Prevention (CDC) guidance recommends …
**Background**: High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared to standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices …
Work presented to the Advisory Committee on Immunization Practices (ACIP) that modeled the potential impact of recommending high-dose, adjuvanted and recombinant vaccines to adults aged 65 and over on seasonal influenza burden in the United States.